Literature DB >> 10748908

Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study.

E Sarti1, P M Schantz, G Avila, J Ambrosio, R Medina-Santillán, A Flisser.   

Abstract

An intervention study with mass treatment against taeniasis to prevent neurocysticercosis due to Taenia solium in a rural community in Mexico was performed in 1991-96. Information and biological samples were obtained at the beginning of the study, at 6 months and at 42 months after mass treatment with praziquantel at a single dose of 5 mg/kg. Prevalence rates of taeniasis were measured by the detection of Taenia coproantigens and Taenia eggs in faeces; neurocysticercosis was suggested by clinical data and by serum antibodies in humans and also in swine. A reduction of 53% after 6 months and of 56% after 42 months for human taeniasis was seen after treatment. Late-onset general seizures decreased 70%. Anti-cysticercus antibodies in the human population were reduced by 75% after 42 months. Antibodies in pigs also showed a significant reduction of 55% after 6 months. In conclusion, an impact of mass chemotherapy against taeniasis to control cysticercosis in the short and long term was demonstrated. Praziquantel for tapeworm treatment should not be given at doses lower than 10 mg/kg. Late-onset convulsive crisis and specific antibodies are good indicators of neurocysticercosis and of exposure to the parasite, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10748908     DOI: 10.1016/s0035-9203(00)90451-6

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  42 in total

Review 1.  Neurocysticercosis--New Millennium, ancient disease and unending debate.

Authors:  G Narula; K S Bawa
Journal:  Indian J Pediatr       Date:  2003-04       Impact factor: 1.967

Review 2.  Prevention and control of Taenia solium taeniasis/cysticercosis in Peru.

Authors:  Robert H Gilman; Armando E Gonzalez; Fernando Llanos-Zavalaga; Victor C W Tsang; Hector H Garcia
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

3.  Study and ranking of determinants of Taenia solium infections by classification tree models.

Authors:  Kabemba E Mwape; Isaac K Phiri; Nicolas Praet; Pierre Dorny; John B Muma; Gideon Zulu; Niko Speybroeck; Sarah Gabriël
Journal:  Am J Trop Med Hyg       Date:  2014-11-17       Impact factor: 2.345

4.  Barriers to Participation in a Community-Based Program to Control Transmission of Taenia solium in Peru.

Authors:  Michelle Beam; Angela Spencer; Lauralee Fernandez; Ruth Atto; Claudio Muro; Percy Vilchez; Ricardo Gamboa; Sandra Olaya; Viterbo Ayvar; Armando E Gonzalez; Hector H Garcia; Seth E O'Neal
Journal:  Am J Trop Med Hyg       Date:  2018-04-12       Impact factor: 2.345

5.  Neurocysticercosis.

Authors:  Pratibha Singhi
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

6.  Taenia solium taeniasis and cysticercosis control and elimination through community-based interventions.

Authors:  Hélène Carabin; Aminata A Traoré
Journal:  Curr Trop Med Rep       Date:  2014-12-01

Review 7.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

8.  Induction of protection against porcine cysticercosis by vaccination with recombinant oncosphere antigens.

Authors:  Ana Flisser; Charles G Gauci; André Zoli; Joel Martinez-Ocaña; Adriana Garza-Rodriguez; Jose Luis Dominguez-Alpizar; Pablo Maravilla; Rossana Rodriguez-Canul; Guillermina Avila; Laura Aguilar-Vega; Craig Kyngdon; Stanny Geerts; Marshall W Lightowlers
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 9.  Taenia solium cysticercosis.

Authors:  Héctor H García; Armando E Gonzalez; Carlton A W Evans; Robert H Gilman
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

Review 10.  Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management.

Authors:  Andrea Sylvia Winkler
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.